Dongyang Xiangsheng Pharmaceutical Technology

Dongyang Xiangsheng Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Dongyang, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology. The company focuses on high-potential cancer targets, with a pipeline led by XS-02, a selective CDK4/6 inhibitor currently in clinical trials for advanced breast cancer and other solid tumors. In addition to its lead program, the company is advancing XS-03, a PI3K inhibitor, and other early-stage candidates designed to address unmet medical needs. Dongyang Xiangsheng leverages its internal medicinal chemistry expertise to develop differentiated treatments that aim to provide high-quality, affordable precision medicines to patients.